Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.41 |
| ▸ | CBFB | Q13951 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
| ▸ | FDPS | P14324 | 3/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9734561 | 0.86 | NPC1 (0.43) | NPC1POLBRAB9AHTTMEN1 | |
| SCHEMBL17129606 | 0.86 | TSHR (0.41) | NPC1POLBRAB9AL3MBTL1CBFB | |
| SCHEMBL30808273 | 0.84 | SLC6A4 (0.57) | HTTMEN1KMT2AL3MBTL1CBFB | |
| SCHEMBL11957393 | 0.84 | L3MBTL1 (0.47) | NPC1POLBRAB9AMEN1KMT2A | |
| SCHEMBL12876990 | 0.84 | CBFB (0.39) | NPC1POLBRAB9AHTTMEN1 | |
| SCHEMBL2408296 | 0.84 | SLC6A4 (0.57) | HTTMEN1KMT2AL3MBTL1CBFB | |
| SCHEMBL2810242 | 0.84 | REN (0.48) | NPC1POLBRAB9AL3MBTL1CA2 | |
| SCHEMBL29521379 | 0.84 | REN (0.48) | NPC1POLBRAB9AL3MBTL1CA2 | |
| SCHEMBL7038976 | 0.83 | MAPT (0.49) | NPC1POLBRAB9AHTTMEN1 | |
| SCHEMBL13185202 | 0.83 | BIRC5 (0.46) | NPC1MEN1KMT2AL3MBTL1BIRC5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872014-B2 | Anaplastic lymphoma kinase modulators and methods of use | EXELIXIS, INC. (US) | 2011-01-18 | — | — | US | disclosed |
| EP-1648455-A4 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2009-03-04 | — | — | EP | disclosed |
| US-20070032515-A1 | Anaplastic lymphoma kinase modulators and methods of use | EXELIXIS, INC. (US) | 2007-02-08 | — | — | US | disclosed |
| EP-1648455-A2 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005009389-A2 | ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032515-A1 | Anaplastic lymphoma kinase modulators and methods of use | ALK, MALT1, BCL6 | NPC1 501/4885POLB 2819/4885RAB9A 3900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.